GRAIL, LLC
1525 O'Brien Drive
Menlo Park
California
94025
United States
Tel: 833-694-2553
Website: https://grail.com/
Email: customerservice@grail.com
About GRAIL, LLC
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.
LEADERSHIP:
CEO: Bob Ragusa
93 articles about GRAIL, LLC
-
In the past few weeks, the biopharma industry has been filled with layoffs and company launches. To learn about job opportunities at some of the industry's top companies, see inside.
-
GRAIL Presents Positive Analytical Validation Data on its Methylation-Based Post-Diagnostic Cancer Research Solution at American Association for Cancer Research (AACR) Annual Meeting 2023
4/19/2023
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today presented analytical validation data on its recently launched methylation-based post-diagnosis solution to accelerate cancer research (abstract LB297).
-
GRAIL Showcases Methylation Platform Performance Across Cancer Continuum With New Data at American Association for Cancer Research (AACR) Annual Meeting
4/11/2023
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, will present new data showcasing the performance of its methylation platform to detect cancer across the early- and post-diagnosis settings at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, April 14-19, 2023.
-
Grail Introduces State-of-the-Art Methylation-Based Solution to Accelerate Cancer Research in the Post-Diagnosis Setting
1/9/2023
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced the availability of a state-of-the-art research use only offering for biopharmaceutical companies.
-
In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here.
-
It was a busy weekend at ESMO 2022 with Merck, Astellas, Seagen, Regeneron, AstraZeneca and GRAIL all presenting data from their various cancer programs.
-
GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022
9/11/2022
GRAIL, LLC announced final results from the interventional PATHFINDER study, which evaluated multi-cancer early detection screening using a blood test and the clinical care pathways following a “cancer signal detected” MCED test result in 6,662 individuals aged 50 years or older, an age group at elevated risk for cancer.
-
CORRECTING and REPLACING GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022
9/11/2022
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced final results from the interventional PATHFINDER study, which evaluated multi-cancer early detection screening using a blood test and the clinical care pathways following a “cancer signal detected” MCED test result in 6,662 individuals aged 50 years or older, an age group at elevated risk for cancer.
-
The Administrative Law Judge overseeing the FTC’s challenge of Illumina’s acquisition of Grail rejected the regulator’s anti-competition argument, Illumina announced Thursday.
-
Grail and National Health Service (NHS) England Complete Enrollment of 140,000 Participants in Largest Study of Multi-Cancer Early Detection Test
7/18/2022
GRAIL, LLC announced today that the NHS-Galleri trial successfully completed enrollment in just over 10 months.
-
GRAIL and Ochsner Health Launch New Initiatives to Improve Cancer Detection Rates in Louisiana
6/3/2022
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and Ochsner Health announced a multi-faceted partnership to improve cancer detection rates in Louisiana using Galleri®, GRAIL’s multi-cancer early detection blood test.
-
GRAIL Announces Strategic Collaboration With AstraZeneca to Develop Companion Diagnostic Tests to Enable the Treatment of Early-Stage Cancer
6/2/2022
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a broad strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca’s therapies.
-
GRAIL and Intermountain Healthcare Expand Partnership to Offer Galleri® Multi-Cancer Early Detection Blood Test to Eligible Patients in Utah
5/17/2022
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and Intermountain Healthcare announced that Galleri®, GRAIL’s groundbreaking multi-cancer early detection blood test, will be offered as a complement to existing single cancer screenings to help advance the delivery of cancer care through early detection.
-
The European Commission has provided an update that it remains unconvinced by the merger, which spells bad news for Illumina.
-
Such a deep, data-driven approach is enabling precision medicine, in particular, which is expanding from oncology to autoimmune diseases and other conditions.
-
GRAIL Announces Partnership with Alignment Health Plan as First Medicare Advantage Plan to Offer Galleri® Multi-Cancer Early Detection Blood Test
12/6/2021
GRAIL, LLC announced today a partnership with Alignment Health Plan, a national Medicare Advantage health plan from Alignment Healthcare (NASDAQ: ALHC), to provide its Medicare Advantage members access to Galleri®, GRAIL’s groundbreaking multi-cancer early detection blood test.
-
Genomics veteran Bob Ragusa is taking over GRAIL, a newly-acquired business unit of Illumina, Inc. He is taking over as CEO Hans Bishop steps down from his role.
-
Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test Galleri
8/18/2021
Illumina, Inc. (NASDAQ: ILMN) announced today that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers using Galleri test.
-
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
-
GRAIL Presents Interventional PATHFINDER Study Data at 2021 ASCO Annual Meeting and Introduces Galleri, a Groundbreaking Multi-Cancer Early Detection Blood Test
6/4/2021
GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today presented the first results from the interventional PATHFINDER study evaluating Galleri™, a multi-cancer early detection